)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vita Life Sciences
Vita Life Sciences (VLS) investor relations material
Vita Life Sciences H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary17 Aug, 2026
Executive summary
Achieved record half-year performance for the six months ended June 2026, with revenue up 6% to $48.3 million and profit before tax up 19% to $8.1 million, supported by broad-based growth and strong consumer sentiment.
Net profit after tax increased 14.9% to $5.5 million year-over-year.
Growth driven by improved operating margins, favorable product mix, disciplined cost management, and capital management.
Financial highlights
Revenue rose 6% year-over-year to $48.3 million for the half year ended June 2026.
Gross profit margin increased by 3 percentage points to 64% (reported as 63.5% in some sources).
EBITDA grew to $8.2 million from $7.0 million, and EBIT increased to $7.7 million from $6.4 million year-over-year.
Profit before tax up 19% to $8.1 million; profit after tax up to $5.5 million from $4.8 million.
Basic EPS improved to 10.22 cents from 8.61 cents; half-year dividend increased to 5.0 cents per share.
Outlook and guidance
Continued distribution expansion and targeted market initiatives in Australia, Malaysia, Singapore, and Vietnam.
Revised China strategy with a new exclusive e-commerce distributor to be implemented in Q3 2026.
Board will monitor economic uncertainties and provide further outlook in Q4.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vita Life Sciences
- Record revenue, higher dividend, and all AGM resolutions passed amid disciplined growth.VLS
AGM 2026 - Record revenue and profit growth, higher dividends, and strong Asia-Pacific momentum.VLSH2 2025
- Revenue and profit rose strongly, led by Asia-Pacific growth and higher marketing investment.VLSH1 2025
- Revenue up 15% and profit before tax up 9%, with strong cash and higher dividend.VLSH1 2024
- Record revenue, increased dividend, and strategic Asian expansion highlighted; all resolutions passed.VLSAGM 2025
- Record revenue and higher dividend, but net profit declined amid increased investment.VLSH2 2024
Next Vita Life Sciences earnings date
H2 202625 Mar, 2027
Vita Life Sciences
Next Vita Life Sciences earnings date
H2 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vita Life Sciences Limited is an Australian healthcare company that develops, manufactures, and distributes vitamins, supplements, and over-the-counter health products. The company operates through various brands, offering a range of nutraceuticals designed to support health and wellness, including products for immune health, cardiovascular support, and general well-being. Vita Life Sciences serves both retail and practitioner channels across the Asia-Pacific region, including Australia, Malaysia, Singapore, and Thailand. Vita Life Sciences Limited is headquartered in Sydney, Australia, and its shares are listed on the ASX.